Takahiro Nishida1, Ryuji Tominaga. 1. Department of Cardiovascular Surgery, Kyushu University Graduate School of Medical Sciences, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. tnishida@heart.med.kyushu-u.ac.jp
Abstract
BACKGROUND: The various uses of biological valves for either aortic or mitral valve replacement have recently increased because of the growing proportion of elderly patients requiring surgery. RESULTS: The durability of recent xenografts has been reported to be over 90 % at 10 years after aortic or mitral valve replacement for elderly patients more than 65 years of age, and therefore the guidelines now recommend the use of bioprostheses for patients over 65 years of age. Bioprostheses are also recommended for valve replacement of the right side of the heart by several authors; however, no clear guidelines are available. Trans-catheter aortic valve replacement and percutaneous pulmonary valve implantation are promising procedures for high-risk patients, although evaluation of the long-term durability of these valves is mandatory. CONCLUSIONS: This article will review the development of the tissue valve for valve surgery.
BACKGROUND: The various uses of biological valves for either aortic or mitral valve replacement have recently increased because of the growing proportion of elderly patients requiring surgery. RESULTS: The durability of recent xenografts has been reported to be over 90 % at 10 years after aortic or mitral valve replacement for elderly patients more than 65 years of age, and therefore the guidelines now recommend the use of bioprostheses for patients over 65 years of age. Bioprostheses are also recommended for valve replacement of the right side of the heart by several authors; however, no clear guidelines are available. Trans-catheter aortic valve replacement and percutaneous pulmonary valve implantation are promising procedures for high-risk patients, although evaluation of the long-term durability of these valves is mandatory. CONCLUSIONS: This article will review the development of the tissue valve for valve surgery.
Authors: Friedrich W Mohr; Sven Lehmann; Volkmar Falk; Sebastian Metz; Claudia Walther; Nico Doll; Ardawan Rastan; Jan Gummert; Thomas Walther Journal: Ann Thorac Surg Date: 2005-03 Impact factor: 4.330
Authors: B Eyskens; T Reybrouck; J Bogaert; S Dymarkowsky; W Daenen; M Dumoulin; M Gewillig Journal: Am J Cardiol Date: 2000-01-15 Impact factor: 2.778
Authors: Peter C Chen; Maggie S Sager; David Zurakowski; Frank A Pigula; Christopher W Baird; John E Mayer; Pedro J Del Nido; Sitaram M Emani Journal: J Thorac Cardiovasc Surg Date: 2011-12-07 Impact factor: 5.209
Authors: Thomas Walther; Marie-Theres Kasimir; Mirko Doss; Gerhard Schuler; Paul Simon; Volker Schächinger; Friedrich W Mohr; Gerhard Wimmer-Greinecker Journal: Eur J Cardiothorac Surg Date: 2010-07-15 Impact factor: 4.191
Authors: U Bortolotti; A Milano; G Thiene; F Guerra; A Mazzucco; M Valente; E Talenti; V Gallucci Journal: J Thorac Cardiovasc Surg Date: 1987-08 Impact factor: 5.209
Authors: U Bortolotti; A Milano; A Mazzucco; F Guerra; M Valente; G Thiene; E Talenti; V Gallucci Journal: Eur J Cardiothorac Surg Date: 1988 Impact factor: 4.191
Authors: Stephan Haussig; Constantin Pleissner; Norman Mangner; Felix Woitek; Marion Zimmer; Philipp Kiefer; Florian Schlotter; Georg Stachel; Sergey Leontyev; David Holzhey; Michael A Borger; Axel Linke Journal: CJC Open Date: 2021-02-01